GlassScriptPhysician profile
Emma Nicolli
NPI 1548008345
$1,889.69
in general payments reported to CMS, 2019-2025
32 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $793 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.70 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $217.24 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Merck Sharp & Dohme LLC | $150.08 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech, INC. | $132.20 | 2024 | Itovebi, Columvi, Polivy |
| Astrazeneca Pharmaceuticals LP | $113.39 | 2024-2025 | Lynparza, Tagrisso, Enhertu |
| Abbvie INC. | $110.81 | 2024-2025 | |
| Gilead Sciences, INC. | $110.24 | 2024-2025 | Trodelvy |
| Genzyme Corporation | $107.51 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.06 | 2024-2025 | Opdualag, Opdivo |
| Eisai INC. | $87.56 | 2024-2025 | |
| Pfizer INC. | $83.85 | 2024-2025 | |
| Array Biopharma INC | $62.59 | 2024-2025 | Mektovi, Xalkori, Braftovi |
| Agios Pharmaceuticals, INC. | $60.91 | 2024-2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $51.21 | 2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $39.95 | 2024-2025 | Jakafi |
| Springworks Therapeutics, INC. | $36.34 | 2024 | Ogsiveo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $35.96 | 2024-2025 | Zoladex |
| Adaptive Biotechnologies Corporation | $34.23 | 2025 | Clonoseq |
| Beone Medicines USA, INC. | $31.61 | 2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $30.17 | 2025 | |
| Stemline Therapeutics INC. | $28.96 | 2024 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $28.43 | 2025 | Fruzaqla |
| Tempus Ai, INC | $26.96 | 2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $24.58 | 2025 | |
| Accord Healthcare, INC. | $23.69 | 2025 | |
| Genmab U.S., INC. | $22.39 | 2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $20.93 | 2025 | Qinlock, Tgct |
| Genentech USA, INC. | $20.72 | 2025 | Venclexta |
| Daiichi Sankyo INC. | $20.50 | 2025 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.48 | 2025 | |
| Sobi, INC | $19.53 | 2024 | |
| Verity Pharmaceuticals INC. | $17.98 | 2025 | Trelstar |
| Puma Biotechnology, INC. | $14.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Nicolli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.